Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • Medical Jobs
  • Medical Matrimony
  • MD Brand Connect
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • MCI News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Aborad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • MCI News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • News
  • Industry
  • Pharma News
  • Novartis in tight spot...

Novartis in tight spot as HC stays grant of patent for Entresto amid generics fight

Farhat NasimWritten by Farhat Nasim Published On 2023-01-13T11:59:01+05:30  |  Updated On 13 Jan 2023 6:29 AM GMT
Novartis in tight spot as HC stays grant of patent for Entresto amid generics fight

New Delhi: Amid the earlier patent of blockbuster heart failure drug Entresto expiring on January 16, 2023 concerns rise for the Swiss multinational pharma firm, Novartis, as the Delhi High Court stayed the patent granted to the drug maker by the Indian Patent Office (IPO) in 2022 for its top selling heart failure therapy Vymada, sold as Entresto (a combination of sacubitril and...

New Delhi: Amid the earlier patent of blockbuster heart failure drug Entresto expiring on January 16, 2023 concerns rise for the Swiss multinational pharma firm, Novartis, as the Delhi High Court stayed the patent granted to the drug maker by the Indian Patent Office (IPO) in 2022 for its top selling heart failure therapy Vymada, sold as Entresto (a combination of sacubitril and valsartan) globally.

The patents of the Entresto fixed dose combination are set to expire on January 16, 2023. The new patent secured by Novartis on December 14, 2022 prohibits companies from launching the chemically combined complex of the sacubitril and valsartan till 2026.

However, Justice Hari Shankar in his order on January 2023 stayed the patent awarded to Novartis, and has asked the Controller of Patents & Designs to hear the opposition to the patent.

The stay comes in response to a writ petition filed by Natco Pharma against the grant of patent by IPO to the pharmaceutical composition comprising combination of sacubitril + valsartan as a sodium salt complex of the Vymada.

Natco filed writ petition citing procedural irregularities and violation of principles of natural justice by the Assistant Controller of Patents & Designs in awarding patent to Novartis drug on December 14, 2022.

Counsel J Sai Deepak, representing Natco argued that the patent was awarded unilaterally to Novartis by the Assistant Controller without giving Natco an opportunity to submit pre-grant opposition as per the procedure laid down in the Section 25(1) of the Patent Act.

A top executive of Natco Pharma told The Economic Times with the court order "everyone" will be able to launch the generic version of the heart failure drug from January 16.

Medical Dialogues team had earlier reported that various pharma firms have been eyeing to produce the generic version of the top selling drug once its patent expires in 2023. To mention, Novartis' latest patent could potentially put a spanner into Indian drug companies' plans to launch generic versions of the blockbuster drug next week.

Also Read: HC Restrains 4 Pharma Firms From Making, Selling Novartis Sacubitril, Valsartan Tablets

Meanwhile commenting on the latest order, Novartis was quoted as saying in a statement by ET, "Novartis is disappointed with the outcome from the Delhi High Court, India, which stayed the grant of IN 414518," said Novartis in a statement.

"Novartis shall review the order carefully before taking appropriate action to defend its Intellectual property. Novartis has faith in the Indian Judicial system and is committed to protecting its patent rights for Entresto/ Vymada," the company added.

novartis natco vymada natco pharma hari shankar entresto delhi patent act delhi high court valsartan generic fixed dose combination sacubitril heart failure drug cardiovascular diseases 
Source : with inputs
Farhat Nasim
Farhat Nasim

    Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

    Show Full Article

    More News

    Next Story
    Similar Posts
    NO DATA FOUND

    Editorial

    Journal Club Today

    Health News Today

    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    X